

Figure 1

Plasmid Name	GENE	Parental Plasmid	Promoter/ Enhancer	Terminator
VR1223	Firefly Lux	VR1012*	CMV	BGH
VR1412	Bacterial LacZ	VR1012*	CMV	BGH
VR2901	Mouse EPO	VR1012*	CMV	BGH
VR2996	Mouse EPO	VR1012	MV/Desmin	BGH
VR3301	Human SEAP	VR1012*	CMV	BGH
VR3502	Rat proinsulin	VR1012*	CMV	BGH
VR4151	Human IFN-omega	VR1055	CMV	mRBG
VR4700	Influenza NP	VR1255**	CMV	mRBG
VR1418	Bacterial LacZ	VR1043	RSV	BGH
VR1255	Firefly Lux	VR1223	CMV	mRBG

Intermediate plasmids

VR1012	none	V1J***	CMV	BGH
VR1043	none	VR1343	RSV	BGH
VR1055	none	VR1255	CMV	mRBG

Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3




Figure 4







Figure 5








Figure 6.

Figure 7




[illegible]

Figure 9





Figure 10



P104 3
Triton X-100 3
NP-40 3
L81 3
P103 3
P105 3
F108 3
L121 3
P65 4
L31 4
F68 5
L64 5
25R4 5
17R4 5
L92 5
L44 5
L101 5
L61 6
L62 6
25R2 7

Figure 11




Figure 12




Figure 13




Figure 14





Figure 15






Figure 16

CTL activity is not inhibited when pDNA +
poloxamer is administered




Figure 16D

effects on IFNw pDNA mediated anti-tumor efficacy




Figure 17







Figure 18

Figure 19



Day 3 luciferase expression after intramuscular administration of VR1255 \pm poloxamer (F68)



Day 3 luciferase expression after intramuscular administration of VR1255 \pm poloxamer (25R2)





Figure 20

Fig 21

Hematocrit levels after a single dose (1 μ g) of VR2901 \pm poloxamer 25R2



Days after injection

Fig 22

Page 1256666

HCT levels after administration of VR2996 + Poloxamer F68




Fig 23

DNA dose response after injection of VR1255 \pm poloxamer (25R2)




Fig. 24

biochem

Time course of expression after delivery of VR1255 \pm 25R2 (0.01%)





Figure 25

Transfection of mouse rectus femoris with VR1412 (pBgal)
± poloxamer 25R2 (0.01%)



Variable	Mean	Standard Deviation	Minimum	Maximum
Age	34.5	10.2	22	55
Gender	0.45	0.50	0	1
Marital Status	0.60	0.49	0	1
Education	12.5	1.5	9	16
Income	3500	1500	1000	8000
Health	0.75	0.43	0	1
Smoking	0.20	0.40	0	1
Alcohol	0.10	0.30	0	1
Exercise	0.30	0.46	0	1
Stress	0.50	0.50	0	1
Depression	0.25	0.43	0	1
Loneliness	0.35	0.48	0	1
Social Support	0.65	0.48	0	1
Life Satisfaction	0.70	0.45	0	1
Quality of Life	0.80	0.40	0	1

pDNA in Na-P + 25R2,
average transfection at 7 days